The rational development of biological response modifiers James E. Talmadge Editorial Pages: 177 - 178
Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha Linville M. MeadowsCeleste LindleyHoward Ozer OriginalPaper Pages: 179 - 187
Strategies for improving antitumor activity utilizing IL-2: Preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2 Mark R. AlbertiniJacquelyn A. HankPaul M. Sondel OriginalPaper Pages: 189 - 198
MTP-PE in liposomes as a biological response modifier in the treatment of cancer: Current status Heiner Frost OriginalPaper Pages: 199 - 204
Clinical trials of bestatin for leukemia and solid tumors K. OtaY. Uzuka OriginalPaper Pages: 205 - 214
Development of immunotherapeutic strategies for the treatment of malignant neoplasms James E. Talmadge OriginalPaper Pages: 215 - 236